Drug Profile
KP 9
Latest Information Update: 10 Jul 2007
Price :
$50
*
At a glance
- Originator Burroughs Wellcome
- Developer Krenitsky Pharmaceuticals
- Class Antidepressants
- Mechanism of Action Monoamine oxidase A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Major depressive disorder
Most Recent Events
- 30 Nov 2000 No-Development-Reported for Depression in USA (Unknown route)
- 20 Jun 1997 Preclinical development for Depression in USA (Unknown route)